Physician profile
Harry S Pan
NPI 1346688538
$2,919.60
in general payments reported to CMS, 2019-2025
29 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $434 · 2021: $735 · 2022: $405 · 2023: $313 · 2024: $186 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.66 | 2019-2023 | Farxiga |
| Gilead Sciences, INC. | $281.21 | 2019-2021 | |
| Dexcom, INC. | $216.05 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $176.08 | 2021 | |
| Amgen INC. | $152.23 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $135.06 | 2019-2025 | Rybelsus, Ozempic |
| Shockwave Medical, INC | $132.56 | 2021 | |
| Abbvie INC. | $124.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.61 | 2023-2024 | |
| Allergan, INC. | $101.52 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.25 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.01 | 2022 | |
| Horizon Therapeutics Plc | $61.99 | 2022-2023 | Krystexxa |
| Lucid Diagnostics INC. | $58.30 | 2022 | |
| Topcon Healthcare Solutions, INC. | $58.25 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $52.81 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $52.22 | 2019-2020 | |
| Exact Sciences Corporation | $48.11 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $47.08 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.67 | 2021-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $45.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.23 | 2021 | |
| Amarin Pharma, INC. | $36.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.77 | 2021 | |
| Abbott Laboratories | $33.23 | 2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $26.82 | 2022-2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $16.24 | 2019 | |
| Bardy Diagnostics, INC. | $15.95 | 2021 | |
| Ethicon US, LLC | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.